Press release

WAYLIVRA▼® (volanesorsen), the first and only therapy for familial chylomicronaemia syndrome, an ultra-rare and life-threatening condition, to be available on the NHS in Scotland

News WAYLIVRA▼® (volanesorsen), the first and only therapy for familial chylomicronaemia syndrome, an ultra-rare and life-threatening condition, to be available on the NHS in Scotland Published date: 09/11/2020 AKC-056-004 | November 2020 View Fullscreen Back to news listing Recent Posts WAYLIVRA▼® (volanesorsen), the first and only therapy for familial chylomicronaemia syndrome, an ultra-rare and life-threatening…

Read More

WAYLIVRA▼® (volanesorsen), the first and only therapy for FCS, an ultra-rare and life-threatening condition, to be available on the NHS in England

News WAYLIVRA▼® (volanesorsen), the first and only therapy for FCS, an ultra-rare and life-threatening condition, to be available on the NHS in England Published date: 18/09/2020 AKCUK-076 | September 2020 View Fullscreen Back to news listing Recent Posts WAYLIVRA▼® (volanesorsen), the first and only therapy for familial chylomicronaemia syndrome, an ultra-rare and life-threatening condition, to…

Read More

Akcea response to draft negative guidance from NICE for WAYLIVRA▼® (volanesorsen), the only therapy for FCS, a devastating and ultra-rare disease

News Akcea response to draft negative guidance from NICE for WAYLIVRA▼® (volanesorsen), the only therapy for FCS, a devastating and ultra-rare disease Published date: 02/01/2020 AKCUK-070 | September 2020 View Fullscreen Back to news listing Recent Posts WAYLIVRA▼® (volanesorsen), the first and only therapy for familial chylomicronaemia syndrome, an ultra-rare and life-threatening condition, to be…

Read More

Tegsedi®▼ (inotersen) to be made available on the NHS in Scotland for people with rare hATTR amyloidosis

News Tegsedi®▼ (inotersen) to be made available on the NHS in Scotland for people with rare hATTR amyloidosis Published date: 15/08/2019 AKCUK-075 | September 2020 View Fullscreen Back to news listing Recent Posts WAYLIVRA▼® (volanesorsen), the first and only therapy for familial chylomicronaemia syndrome, an ultra-rare and life-threatening condition, to be available on the NHS…

Read More

NICE issues final guidance for Tegsedi®▼ (inotersen) for hATTR amyloidosis

News NICE issues final guidance for Tegsedi®▼ (inotersen) for hATTR amyloidosis Published date: 23/05/2019 AKCUK-072 | September 2020 View Fullscreen Back to news listing Recent Posts WAYLIVRA▼® (volanesorsen), the first and only therapy for familial chylomicronaemia syndrome, an ultra-rare and life-threatening condition, to be available on the NHS in Scotland Akcea celebrates third global Familial…

Read More

Akcea and Ionis Announce Authorisation of WAYLIVRA▼® (volanesorsen) in the European Union

News Akcea and Ionis Announce Authorisation of WAYLIVRA▼® (volanesorsen) in the European Union Published date: 08/05/2019 AKCUK-074 | September 2020 View Fullscreen Back to news listing Recent Posts WAYLIVRA▼® (volanesorsen), the first and only therapy for familial chylomicronaemia syndrome, an ultra-rare and life-threatening condition, to be available on the NHS in Scotland Akcea celebrates third…

Read More

Tegsedi™▼ (inotersen) to be made available on the NHS in England for people with hATTR amyloidosis

News Tegsedi™▼ (inotersen) to be made available on the NHS in England for people with hATTR amyloidosis Published date: 16/04/2019 AKCUK-071 | September 2020 View Fullscreen Back to news listing Recent Posts WAYLIVRA▼® (volanesorsen), the first and only therapy for familial chylomicronaemia syndrome, an ultra-rare and life-threatening condition, to be available on the NHS in…

Read More

Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRA™▼ (volanesorsen)

News Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRA™▼ (volanesorsen) Published date: 01/03/2019 AKCUK-073 | September 2020 View Fullscreen Back to news listing Recent Posts WAYLIVRA▼® (volanesorsen), the first and only therapy for familial chylomicronaemia syndrome, an ultra-rare and life-threatening condition, to be available on the NHS in Scotland Akcea celebrates third global…

Read More